These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 33624286)

  • 1. Mycophenolic Acid Exposure Prediction Using Machine Learning.
    Woillard JB; Labriffe M; Debord J; Marquet P
    Clin Pharmacol Ther; 2021 Aug; 110(2):370-379. PubMed ID: 33624286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tacrolimus Exposure Prediction Using Machine Learning.
    Woillard JB; Labriffe M; Debord J; Marquet P
    Clin Pharmacol Ther; 2021 Aug; 110(2):361-369. PubMed ID: 33253425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maximum a posteriori Bayesian estimation of mycophenolic Acid area under the concentration-time curve: is this clinically useful for dosage prediction yet?
    Staatz CE; Tett SE
    Clin Pharmacokinet; 2011 Dec; 50(12):759-72. PubMed ID: 22087863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and validation of limited sampling strategies for the estimation of mycophenolic acid area under the curve in adult kidney and liver transplant recipients receiving concomitant enteric-coated mycophenolate sodium and tacrolimus.
    Pawinski T; Luszczynska P; Durlik M; Majchrzak J; Baczkowska T; Chrzanowska M; Sobiak J; Glyda M; Kuriata-Kordek M; Kamińska D; Krajewska M; Klinger M
    Ther Drug Monit; 2013 Dec; 35(6):760-9. PubMed ID: 24192641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in stable renal transplant patients.
    Le Guellec C; Bourgoin H; Büchler M; Le Meur Y; Lebranchu Y; Marquet P; Paintaud G
    Clin Pharmacokinet; 2004; 43(4):253-66. PubMed ID: 15005639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimation of drug exposure by machine learning based on simulations from published pharmacokinetic models: The example of tacrolimus.
    Woillard JB; Labriffe M; Prémaud A; Marquet P
    Pharmacol Res; 2021 May; 167():105578. PubMed ID: 33775863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure.
    Tett SE; Saint-Marcoux F; Staatz CE; Brunet M; Vinks AA; Miura M; Marquet P; Kuypers DR; van Gelder T; Cattaneo D
    Transplant Rev (Orlando); 2011 Apr; 25(2):47-57. PubMed ID: 21190834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population Pharmacokinetic Modelling and Bayesian Estimation of Tacrolimus Exposure: Is this Clinically Useful for Dosage Prediction Yet?
    Brooks E; Tett SE; Isbel NM; Staatz CE
    Clin Pharmacokinet; 2016 Nov; 55(11):1295-1335. PubMed ID: 27138787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Limited sampling strategy for simultaneous estimation of the area under the concentration-time curve of tacrolimus and mycophenolic acid in adult renal transplant recipients.
    Miura M; Satoh S; Niioka T; Kagaya H; Saito M; Hayakari M; Habuchi T; Suzuki T
    Ther Drug Monit; 2008 Feb; 30(1):52-9. PubMed ID: 18223463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mycophenolic mofetil optimized pharmacokinetic modelling, and exposure-effect associations in adult heart transplant recipients.
    Woillard JB; Saint-Marcoux F; Monchaud C; Youdarène R; Pouche L; Marquet P
    Pharmacol Res; 2015 Sep; 99():308-15. PubMed ID: 26192348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Limited sampling model for advanced mycophenolic acid therapeutic drug monitoring after liver transplantation.
    Langers P; Press RR; Inderson A; Cremers SC; den Hartigh J; Baranski AG; van Hoek B
    Ther Drug Monit; 2014 Apr; 36(2):141-7. PubMed ID: 24081208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defining algorithms for efficient therapeutic drug monitoring of mycophenolate mofetil in heart transplant recipients.
    Kaczmarek I; Bigdeli AK; Vogeser M; Mueller T; Beiras-Fernandez A; Kaczmarek P; Schmoeckel M; Meiser B; Reichart B; Ueberfuhr P
    Ther Drug Monit; 2008 Aug; 30(4):419-27. PubMed ID: 18641552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early phase limited sampling strategy characterizing tacrolimus and mycophenolic acid pharmacokinetics adapted to the maintenance phase of renal transplant patients.
    Miura M; Satoh S; Niioka T; Kagaya H; Saito M; Hayakari M; Habuchi T; Suzuki T
    Ther Drug Monit; 2009 Aug; 31(4):467-74. PubMed ID: 19571775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of 3 estimation methods of mycophenolic acid AUC based on a limited sampling strategy in renal transplant patients.
    Hulin A; Blanchet B; Audard V; Barau C; Furlan V; Durrbach A; Taïeb F; Lang P; Grimbert P; Tod M
    Ther Drug Monit; 2009 Apr; 31(2):224-32. PubMed ID: 19214145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maximum a posteriori bayesian estimation of mycophenolic acid pharmacokinetics in renal transplant recipients at different postgrafting periods.
    Prémaud A; Le Meur Y; Debord J; Szelag JC; Rousseau A; Hoizey G; Toupance O; Marquet P
    Ther Drug Monit; 2005 Jun; 27(3):354-61. PubMed ID: 15905807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of an abbreviated pharmacokinetic profile for the estimation of mycophenolic acid exposure in pediatric renal transplant recipients.
    Weber LT; Hoecker B; Armstrong VW; Oellerich M; Tönshoff B
    Ther Drug Monit; 2006 Oct; 28(5):623-31. PubMed ID: 17038876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids are dose dependent and not reflected by trough plasma concentration: a prospective study in 100 de novo renal allograft recipients.
    Kuypers DR; Claes K; Evenepoel P; Maes B; Coosemans W; Pirenne J; Vanrenterghem Y
    J Clin Pharmacol; 2003 Aug; 43(8):866-80. PubMed ID: 12953344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation and Validation of a Limited Sampling Strategy to Monitor Mycophenolic Acid Exposure in Children With Nephrotic Syndrome.
    Benz MR; Ehren R; Kleinert D; Müller C; Gellermann J; Fehrenbach H; Schmidt H; Weber LT
    Ther Drug Monit; 2019 Dec; 41(6):696-702. PubMed ID: 31425441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Machine learning algorithms to estimate everolimus exposure trained on simulated and patient pharmacokinetic profiles.
    Labriffe M; Woillard JB; Debord J; Marquet P
    CPT Pharmacometrics Syst Pharmacol; 2022 Aug; 11(8):1018-1028. PubMed ID: 35599364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.